<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731874</url>
  </required_header>
  <id_info>
    <org_study_id>0608008711</org_study_id>
    <nct_id>NCT00731874</nct_id>
  </id_info>
  <brief_title>Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status</brief_title>
  <acronym>TIMELY</acronym>
  <official_title>Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status by Biopsy and mRNA Profiles (TIMELY Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tacrolimus (Prograf) is a medication that is commonly used in patients who receive a kidney&#xD;
      transplant. It is considered to be one of the most important medications that prevent&#xD;
      rejection of the transplant kidney by suppressing the immune system. Although tacrolimus is&#xD;
      good at preventing rejection, it does have some unwanted side effects. These side effects&#xD;
      include high blood pressure, increase in blood sugar, headache, and tremor. In addition,&#xD;
      tacrolimus causes some damage to the transplant kidney over time, by causing healthy tissue&#xD;
      to turn into scar tissue that does not function as well as healthy tissue. Therefore, kidney&#xD;
      function may be reduced over time. In the first three months after kidney transplant, Prograf&#xD;
      levels are kept between 8 to 10 ng/mL. This study will compare two groups of patients that&#xD;
      will both have their tacrolimus dose reduced slowly over three months to prevent rejection&#xD;
      while decreasing the risk of causing toxic effects to the kidney. One group will have their&#xD;
      Prograf levels kept between 6 and 8 ng/mL, while the second group will have their levels kept&#xD;
      between 3 and 5 ng/mL. We will then compare the two groups to see if there are any&#xD;
      differences in their kidney function over time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the safety and efficacy of an&#xD;
      immunosuppression-minimizing regimen consisting initially of Thymoglobulin induction in&#xD;
      combination with tacrolimus, mycophenolate mofetil, and rapid steroid withdrawal. The&#xD;
      protocol will minimize long-term calcineurin inhibitor exposure and toxicity by weaning&#xD;
      tacrolimus starting at 3 months after transplantation. Patients will be eligible to&#xD;
      participate in this study only if they have already consented to participate in another study&#xD;
      entitled &quot;The use of urinary PCR test to help detect rejection in kidney transplant&#xD;
      patients&quot;. In &quot;The use of urinary PCR test to help detect rejection in kidney transplant&#xD;
      patients&quot;, kidney allograft status (ie. whether or not there is any immunologic activity in&#xD;
      the transplant kidney)is characterized with the use of protocol biopsies, diagnostic&#xD;
      biopsies, and urinary PCR profiles. At 3 months after transplant, these patients are on an&#xD;
      immunosuppression regimen consisting of tacrolimus (Prograf) and mycophenolate mofetil&#xD;
      (CellCept). Prograf dosing is managed through the measurement of trough levels. For the first&#xD;
      3 months after transplant, patients are maintained at a trough level between 8 to 10 ng/ml.&#xD;
      After 3 months, this target level is lowered in order to minimize long-term exposure to&#xD;
      immunosuppressive agents. However, there is no consensus as to what the proper level should&#xD;
      be after the first 3 months. Therefore, this study will randomize patients to 2 groups, one&#xD;
      group will have their trough level targeted between 6 to 8 ng/mL while the other group will&#xD;
      have their trough targeted between 3 and 5 ng/mL. By doing this study, we hope to determine&#xD;
      which trough level is best, both for protecting the patient from rejection and protecting the&#xD;
      patient from the adverse effects of the immunosuppressive medications.&#xD;
&#xD;
      At New York Weill Cornell Center, we are in a unique position to attempt immunosuppression&#xD;
      minimization due to our ability to non-invasively monitor patients using their urine.&#xD;
      Previous investigations performed at this center have demonstrated the diagnostic accuracy of&#xD;
      mRNA levels of cytotoxic attack molecules in urinary cells. Preliminary data has shown that&#xD;
      during acute rejection, Granzyme B and Perforin are strongly expressed in the urine. The&#xD;
      sensitivity of the uPCR test was 88% with a specificity of 79%. All kidney transplant&#xD;
      recipients at our center are invited to participate in the research study entitled &quot;The use&#xD;
      of urinary PCR test to help detect rejection in kidney transplant patients&quot;. In this&#xD;
      protocol, serial analyses of urinary cells are performed to determine 1) if changes in mRNA&#xD;
      levels will predict clinical acute rejection and 2) if these levels correlate with the&#xD;
      presence of subclinical acute rejection. Kidney transplant recipients have serial urinary PCR&#xD;
      measurements. In addition, patients undergo protocol biopsies of the transplant kidney at 3,&#xD;
      15, and 36 months after transplant. The biopsies help to show the correlation between the PCR&#xD;
      results and the pathology of the kidney. It may also serve to detect rejection when the blood&#xD;
      tests or urinary PCR do not show it. In a small subset of patients, urinary gene expression&#xD;
      profile of cytotoxic attack molecules was able to predict acute rejection prior to clinical&#xD;
      diagnosis by renal allograft biopsy.&#xD;
&#xD;
      Because we have the ability to monitor our transplant recipients using the urinary PCR&#xD;
      protocol, we can safely minimize tacrolimus exposure over time by monitoring patients&#xD;
      non-invasively on a real-time basis. Minimization of immunosuppression over time in a kidney&#xD;
      transplant recipient is important in order to prevent or minimize some of the leading causes&#xD;
      of kidney graft loss (defined as return to dialysis). Although immunosuppressive medications&#xD;
      are excellent at preventing rejection, they do have detrimental effects on the cardiovascular&#xD;
      system as well as to the transplant kidney itself. One major cause of kidney graft loss today&#xD;
      is chronic allograft nephropathy (CAN). Formerly known as &quot;chronic rejection&quot;, CAN has been&#xD;
      described as the progressive decline in allograft function that occurs months or years after&#xD;
      transplantation, and it is the second leading cause of kidney graft loss. Biopsies of kidney&#xD;
      allografts with CAN may show inflammation, fibrosis, glomerulosclerosis, tubular atrophy, and&#xD;
      vascular smooth muscle proliferation. The scarring and fibrosis associated with CAN is&#xD;
      generally irreversible. A new goal within the modern transplant arena is to prevent CAN from&#xD;
      occurring by:&#xD;
&#xD;
        1. decreasing early acute rejection episodes&#xD;
&#xD;
        2. decreasing calcineurin inhibitor-related nephrotoxicity&#xD;
&#xD;
      With the use of modern immunosuppressive agents and induction therapy, we have already&#xD;
      decreased early acute rejection episodes significantly. At this time, we now want to begin to&#xD;
      study the potentially beneficial effects that calcineurin inhibitor withdrawal may have on&#xD;
      kidney function as well as long-term graft survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A higher rate of late rejection was seen in the low tacrolimus arm.&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Biopsy-confirmed Acute Rejection and/or Progression of Histologically Proven Chronic Allograft Nephropathy at 15 Months After Transplantation.</measure>
    <time_frame>15 months post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>36 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival</measure>
    <time_frame>36 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Incidence and Severity of Interstitial Fibrosis/Tubular Atrophy (IF/TA) From the Baseline 3-month Biopsy to the 36-month Biopsy</measure>
    <time_frame>36 months post-transplant</time_frame>
    <description>Compared to the baseline biopsy performed at the time of study entry at 3 months, was there new development (incidence) or progression (severity) of interstitial fibrosis/tubular atrophy (formerly called chronic allograft nephropathy) in the biopsy performed at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function (Estimated Glomerular Filtration Rate)</measure>
    <time_frame>36 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Donor Specific Antibody (DSA)</measure>
    <time_frame>36 months post-transplant</time_frame>
    <description>Percent of subjects who developed new donor specific antibody (mean fluorescence intensity &gt; 3,000) after enrollment, within 36 months of transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Rejection</measure>
    <time_frame>36 months post-transplant</time_frame>
    <description>Incidence of biopsy-proven acute rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Acute Rejection (by Banff Criteria and Need for Anti-lymphocyte Agents to Treat Acute Rejection)</measure>
    <time_frame>36 months post-transplant</time_frame>
    <description>The severity of acute rejection may be assessed by the Banff criteria. The Banff Classification of Allograft Pathology is an international consensus classification for the reporting of renal allograft biopsies, and provides critical information enabling the diagnosis and grading of pathologic changes, can help to predict response to treatment, and can help to determine the long-term prognosis of the organ. Anti-lymphocyte agents (specifically rabbit anti-thymocyte globulin) are used to treat more severe cases of acute rejection, and thus may serve as a surrogate marker of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Opportunistic Infection</measure>
    <time_frame>36 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of New Onset Diabetes Mellitus</measure>
    <time_frame>36 months post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Arm 1 (6 to 8 ng/mL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Target tacrolimus trough concentration of 6 to 8 ng/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (3 to 5 ng.mL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Target tacrolimus trough concentration of 3 to 5 ng/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Dosed to achieve target trough concentrations.</description>
    <arm_group_label>Arm 1 (6 to 8 ng/mL)</arm_group_label>
    <arm_group_label>Arm 2 (3 to 5 ng.mL)</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Renal allograft recipients who received a steroid-sparing immunosuppression protocol&#xD;
             with rabbit anti-thymocyte globulin (Thymoglobulin) induction&#xD;
&#xD;
          -  Patient must have previously enrolled in protocol entitled &quot;The use of urinary PCR&#xD;
             test to help detect rejection in kidney transplant patients&quot;&#xD;
&#xD;
          -  Recipients must agree to undergo all standard post-transplant protocol biopsies&#xD;
&#xD;
          -  Recipients must be at least 3 months post-transplant and the three most recent urinary&#xD;
             profiles must demonstrate immunologic quiescence as determined by measurement of&#xD;
             Granzyme B and Perforin copy numbers&#xD;
&#xD;
          -  Patient must provide informed consent to participate in the research study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is a high-risk recipient (defined as peak or current PRA &gt;50% or a&#xD;
             re-transplant recipient who lost prior graft within 1 year due to immunologic reasons)&#xD;
&#xD;
          -  Patients who require maintenance steroids for another medical condition (such as&#xD;
             asthma)&#xD;
&#xD;
          -  Patients who are taking less than 1 gram/day of mycophenolate mofetil&#xD;
&#xD;
          -  Multiple organ transplant recipients (such as kidney-pancreas)&#xD;
&#xD;
          -  Patients with one or more acute rejection episodes within the first 3 months after&#xD;
             transplant&#xD;
&#xD;
          -  Three-month protocol biopsy showing clinical acute rejection (BANFF grade 1a or&#xD;
             higher)&#xD;
&#xD;
          -  Patient with documented or suspected non-compliance with transplant medications in the&#xD;
             first 3 months after transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandip Kapur, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College/NewYork-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <results_first_submitted>December 21, 2015</results_first_submitted>
  <results_first_submitted_qc>December 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2016</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Minimization</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>Thymoglobulin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>34 subjects consented for the study; 11 were enrolled but not randomized due to the following: withdrew consent/refused transplant biopsy (n=4); donor specific antibody detected during screening (n=3); excluded by findings of kidney transplant biopsy (n=2); fluctuation in renal function (n=1); study terminated prior to randomization (n=1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
          <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
          <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
          <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
          <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.4" spread="11.3"/>
                    <measurement group_id="B2" value="56.1" spread="10.2"/>
                    <measurement group_id="B3" value="52.7" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Biopsy-confirmed Acute Rejection and/or Progression of Histologically Proven Chronic Allograft Nephropathy at 15 Months After Transplantation.</title>
        <time_frame>15 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biopsy-confirmed Acute Rejection and/or Progression of Histologically Proven Chronic Allograft Nephropathy at 15 Months After Transplantation.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival</title>
        <time_frame>36 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Survival</title>
        <time_frame>36 months post-transplant</time_frame>
        <population>Data are not included for one subject because one subject was lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival</title>
          <population>Data are not included for one subject because one subject was lost to follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incidence and Severity of Interstitial Fibrosis/Tubular Atrophy (IF/TA) From the Baseline 3-month Biopsy to the 36-month Biopsy</title>
        <description>Compared to the baseline biopsy performed at the time of study entry at 3 months, was there new development (incidence) or progression (severity) of interstitial fibrosis/tubular atrophy (formerly called chronic allograft nephropathy) in the biopsy performed at 36 months.</description>
        <time_frame>36 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incidence and Severity of Interstitial Fibrosis/Tubular Atrophy (IF/TA) From the Baseline 3-month Biopsy to the 36-month Biopsy</title>
          <description>Compared to the baseline biopsy performed at the time of study entry at 3 months, was there new development (incidence) or progression (severity) of interstitial fibrosis/tubular atrophy (formerly called chronic allograft nephropathy) in the biopsy performed at 36 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Progression of IFTA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>New IFTA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Biopsy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Data</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function (Estimated Glomerular Filtration Rate)</title>
        <time_frame>36 months post-transplant</time_frame>
        <population>Data are not included for one subject because one subject was lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function (Estimated Glomerular Filtration Rate)</title>
          <population>Data are not included for one subject because one subject was lost to follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>eGFR&gt;60</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>eGFR 50-59</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>eGFR 40-49</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>eGFR 30-39</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>eGFR 20-29</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Donor Specific Antibody (DSA)</title>
        <description>Percent of subjects who developed new donor specific antibody (mean fluorescence intensity &gt; 3,000) after enrollment, within 36 months of transplant</description>
        <time_frame>36 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Donor Specific Antibody (DSA)</title>
          <description>Percent of subjects who developed new donor specific antibody (mean fluorescence intensity &gt; 3,000) after enrollment, within 36 months of transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute Rejection</title>
        <description>Incidence of biopsy-proven acute rejection</description>
        <time_frame>36 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Rejection</title>
          <description>Incidence of biopsy-proven acute rejection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Acute Rejection (by Banff Criteria and Need for Anti-lymphocyte Agents to Treat Acute Rejection)</title>
        <description>The severity of acute rejection may be assessed by the Banff criteria. The Banff Classification of Allograft Pathology is an international consensus classification for the reporting of renal allograft biopsies, and provides critical information enabling the diagnosis and grading of pathologic changes, can help to predict response to treatment, and can help to determine the long-term prognosis of the organ. Anti-lymphocyte agents (specifically rabbit anti-thymocyte globulin) are used to treat more severe cases of acute rejection, and thus may serve as a surrogate marker of severity.</description>
        <time_frame>36 months post-transplant</time_frame>
        <population>Data reported only for those subjects who developed acute rejection during the study, per protocol. Three of the 5 subjects in Arm 2 with rejection were treated with rabbit anti-thymocyte globulin.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Acute Rejection (by Banff Criteria and Need for Anti-lymphocyte Agents to Treat Acute Rejection)</title>
          <description>The severity of acute rejection may be assessed by the Banff criteria. The Banff Classification of Allograft Pathology is an international consensus classification for the reporting of renal allograft biopsies, and provides critical information enabling the diagnosis and grading of pathologic changes, can help to predict response to treatment, and can help to determine the long-term prognosis of the organ. Anti-lymphocyte agents (specifically rabbit anti-thymocyte globulin) are used to treat more severe cases of acute rejection, and thus may serve as a surrogate marker of severity.</description>
          <population>Data reported only for those subjects who developed acute rejection during the study, per protocol. Three of the 5 subjects in Arm 2 with rejection were treated with rabbit anti-thymocyte globulin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mixed T cell and Antibody Mediated Rejection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Antibody Mediated Rejection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Opportunistic Infection</title>
        <time_frame>36 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Opportunistic Infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of New Onset Diabetes Mellitus</title>
        <time_frame>36 months post-transplant</time_frame>
        <population>Only subjects who did not have a diagnosis of diabetes mellitus at transplant are included, per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
            <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of New Onset Diabetes Mellitus</title>
          <population>Only subjects who did not have a diagnosis of diabetes mellitus at transplant are included, per protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 (Target Tacrolimus 6 to 8 ng/mL)</title>
          <description>Target tacrolimus trough concentration of 6 to 8 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 (Target Tacrolimus 3 to 5 ng/mL)</title>
          <description>Target tacrolimus trough concentration of 3 to 5 ng/mL&#xD;
Tacrolimus: Dosed to achieve target trough concentrations.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus viremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Strongyloides infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Hip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Antibody-mediated rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Non-melanoma skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The population reported is small because the study was stopped early due to the increase in late antibody mediated rejection (occurring after month 15) that was seen in Arm 2 (target tacrolimus trough 3 to 5 ng/mL).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Meredith J Aull</name_or_title>
      <organization>Weill Cornell Medical College/Division of Transplant Surgery</organization>
      <phone>(212) 746-0727</phone>
      <email>mea9008@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

